The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 346:1399-1400 May 2, 2002 Number 18
NextNext

Anti–TNF-{alpha} Therapy for Ankylosing Spondylitis — A Specific or Nonspecific Treatment?

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Gorman, J. D.
-PubMed Citation
The spondyloarthropathies comprise ankylosing spondylitis, reactive arthritis, arthritis that accompanies inflammatory bowel disease, some forms of psoriatic arthritis, and undifferentiated forms of spondyloarthropathy. The report in this issue of the Journal by Gorman et al.1 focuses on ankylosing spondylitis, a seronegative spondyloarthropathy that is associated with HLA-B27 in about 90 percent of patients. HLA-B27 has a role in the binding of antigenic peptides and in their presentation to CD8+ T cells. HLA-B27–restricted cytotoxic T cells with specificity for bacteria, viral peptides, or autoantigens that cause arthritis, such as peptides derived from the HLA-B27 molecule itself, have been identified in patients . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.